BEAN: Apremilast in children with oral ulcers associated with Behçet's disease

Phase 3, randomised, double-blind trial in Behçet's disease (BD) comparing Apremilast with Placebo → Apremilast (2 arms). Primary endpoint: Area under the curve (AUC) for the number of oral ulcers from baseline to week 12. Planned start Sep 2023; status: authorised.